Eliem Therapeutics Inc. (ELYM)
NASDAQ: ELYM
· Real-Time Price · USD
5.11
-0.05 (-0.97%)
At close: Oct 02, 2024, 10:00 PM
Eliem Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -98.23M | -79.15M | -69.12M | -64.19M | -14.53M | -35.12M | -39.24M | -44.95M | -54.33M | -45.24M | -48.03M | -47.96M | -42.08M | -47.48M | -51.8M | -44.44M | -37.35M |
Depreciation & Amortization | -2.02M | -1.42M | 259K | 428K | 428K | n/a | -784K | -784K | -491K | 193K | 856K | 856K | 563K | 370K | n/a | n/a | n/a |
Stock-Based Compensation | 8.83M | 7.28M | 5.1M | 2.83M | 3.1M | 12.81M | 13.5M | 14.63M | 15.62M | 6.99M | 6.25M | 5.7M | 4.98M | 3.74M | 3.06M | 1.87M | 870K |
Other Working Capital | -2.54M | -3.19M | 2.34M | 11.05M | 6.38M | 6.91M | 5.08M | -263K | -125K | 881K | 3.01M | -4.39M | -2.44M | -4.32M | -6.64M | -2.33M | -3.4M |
Other Non-Cash Items | 54.28M | 54.8M | 52.76M | 52.16M | -932K | -1.56M | -2.04M | -1.26M | 555K | 1.14M | 3.32M | 3.21M | 2.16M | 13.32M | 20.3M | 20.46M | 20.52M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | -1.39M | -1.39M | -1.39M | -1.58M | -2.04M | -2.04M | -2.04M | -1.84M | n/a | n/a | n/a |
Change in Working Capital | -2.1M | -2.73M | 1.45M | 10.23M | 5.58M | 3.76M | 1.86M | -2.92M | -2.65M | 210K | 1.91M | -5.37M | -3.69M | -4.17M | -5.37M | -1.11M | -2.55M |
Operating Cash Flow | -35.78M | -22.17M | -10.99M | 57K | -7.24M | -20.6M | -28.1M | -35.77M | -41.77M | -37.37M | -36.8M | -45.6M | -40.11M | -36.07M | -33.81M | -23.23M | -18.51M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | -4.64M | -4.64M | -4.64M | -4.64M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 8.28M | 8.28M | 8.28M |
Purchase of Investments | -262.74M | -203.99M | -71.79M | -2.46M | -41M | -58.45M | -65.16M | -109.44M | -79.83M | -87.96M | -89.3M | -149.48M | -140.55M | -114.97M | -106.92M | n/a | n/a |
Sales Maturities Of Investments | -13.75M | -16M | 50.5M | 81M | 117.93M | 127.43M | 111.67M | 136.42M | 124.11M | 122.4M | 101.41M | 46.16M | 21.55M | n/a | n/a | n/a | n/a |
Other Investing Acitivies | -5M | 8.75M | 8.79M | 8.82M | 13.81M | 68.98K | 46.51K | 8.53M | 8.54M | 4.5M | -3.56M | -118.99M | -119M | -114.97M | -98.84M | 8.08M | 8.08M |
Investing Cash Flow | -286.13M | -229.63M | -30.93M | 68.89M | 76.94M | 68.98M | 46.51M | 26.98M | 44.27M | 34.44M | 12.11M | -103.32M | -119M | -114.97M | -98.84M | 8.08M | 8.08M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -2.14M | -2.14M | -6.69M | -6.69M | -6.69M | -6.69M | -2.14M | -2.14M | n/a |
Other Financial Acitivies | 141.65M | 141.67M | 130.98M | 129.23M | 855K | 841K | 553K | 25K | 2.14M | 2.14M | 2.18M | 85.32M | 85.33M | 85.43M | 85.4M | 2.25M | 105K |
Financial Cash Flow | 132.7M | 132.71M | 130.98M | 129.23M | 855K | 841K | 553K | 25K | -2.14M | -2.14M | -2.1M | 81.04M | 143.15M | 177.23M | 182.12M | 98.97M | 39.01M |
Net Cash Flow | -152.98M | -82.85M | 88.82M | 197.85M | 70.59M | 49.53M | 21.41M | -7.31M | 2.51M | -3.34M | -26.88M | -66.88M | -15.98M | 26.43M | 50.13M | 84.24M | 28.93M |
Free Cash Flow | -35.78M | -22.17M | -10.99M | 57K | -7.24M | -20.6M | -28.1M | -35.77M | -41.77M | -37.37M | -36.8M | -45.6M | -40.11M | -36.07M | -33.81M | -23.23M | -18.51M |